A declaration from the Food and Drug Administration that an uncompleted Phase III trial’s design, clinical endpoints, and statistical analyses are acceptable for FDA approval.
Menu
A declaration from the Food and Drug Administration that an uncompleted Phase III trial’s design, clinical endpoints, and statistical analyses are acceptable for FDA approval.
Use our tool to look up the definition of terms in our glossary.
©2023 Trilogy Writing & Consulting GmbH | Impressum (Legal Information & Cookie Policy)